XML 49 R31.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Revenue (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Revenue from Contract with Customer [Abstract] |
Schedule of Disaggregation of Revenue | The following table summarizes our revenue recognized in our consolidated statements of operations:
| 2023 |  | 2022 |  | 2021
Net product revenue | $ | 28,813.9 |  |  | $ | 25,462.8 |  |  | $ | 25,957.9 |
Collaboration and other revenue(1) | 5,310.2 |  |  | 3,078.6 |  |  | 2,360.5 |
Revenue | $ | 34,124.1 |  |  | $ | 28,541.4 |  |  | $ | 28,318.4 |
(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $191.6 million, $163.4 million, and $175.0 million during the years ended December 31, 2023, 2022, and 2021, respectively. The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product:
|  |  | U.S. |  | Outside U.S.
|  |  | 2023 |  | 2022 |  | 2021 |  | 2023 |  | 2022 |  | 2021
Diabetes and obesity: |  |  |  |  |  |  |  |  |  |  |
Trulicity® | $ | 5,433.3 |  |  | $ | 5,688.8 |  |  | $ | 4,914.4 |  |  | $ | 1,699.2 |  |  | $ | 1,750.9 |  |  | $ | 1,557.6 |
Mounjaro® | 4,834.2 |  |  | 366.6 |  |  | — |  |  | 328.9 |  |  | 115.9 |  |  | — |
Jardiance(1) | 1,600.4 |  |  | 1,194.5 |  |  | 807.3 |  |  | 1,144.2 |  |  | 871.5 |  |  | 683.5 |
Humalog® (2) | 863.2 |  |  | 1,191.9 |  |  | 1,320.7 |  |  | 800.2 |  |  | 868.7 |  |  | 1,132.3 |
Humulin® | 610.1 |  |  | 730.2 |  |  | 832.9 |  |  | 242.0 |  |  | 289.2 |  |  | 389.6 |
Basaglar® (3) | 443.1 |  |  | 470.7 |  |  | 588.3 |  |  | 285.2 |  |  | 289.7 |  |  | 304.2 |
Baqsimi | 645.7 |  |  | 110.4 |  |  | 96.4 |  |  | 31.9 |  |  | 28.9 |  |  | 16.8 |
Zepbound® | 175.8 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Other diabetes and obesity | 175.0 |  |  | 158.0 |  |  | 159.3 |  |  | 355.2 |  |  | 338.9 |  |  | 384.8 |
Total diabetes and obesity | 14,780.8 |  |  | 9,911.1 |  |  | 8,719.3 |  |  | 4,886.8 |  |  | 4,553.7 |  |  | 4,468.8 |
Oncology: |  |  |  |  |  |  |  |  |  |  |
Verzenio® | 2,509.0 |  |  | 1,653.2 |  |  | 834.9 |  |  | 1,354.3 |  |  | 830.3 |  |  | 515.0 |
Cyramza® | 402.3 |  |  | 351.4 |  |  | 358.1 |  |  | 572.4 |  |  | 620.0 |  |  | 674.8 |
Erbitux® | 528.9 |  |  | 500.1 |  |  | 481.8 |  |  | 67.6 |  |  | 66.4 |  |  | 66.4 |
Tyvyt® | — |  |  | — |  |  | — |  |  | 393.4 |  |  | 293.3 |  |  | 418.1 |
Alimta® | 72.9 |  |  | 543.7 |  |  | 1,233.9 |  |  | 144.6 |  |  | 384.0 |  |  | 827.5 |
Other oncology | 283.9 |  |  | 169.7 |  |  | 120.1 |  |  | 329.0 |  |  | 254.1 |  |  | 210.7 |
Total oncology | 3,797.0 |  |  | 3,218.1 |  |  | 3,028.8 |  |  | 2,861.3 |  |  | 2,448.1 |  |  | 2,712.5 |
Immunology: |  |  |  |  |  |  |  |  |  |  |
Taltz® | 1,831.6 |  |  | 1,724.6 |  |  | 1,542.4 |  |  | 928.0 |  |  | 757.4 |  |  | 670.4 |
Olumiant® (4) | 225.5 |  |  | 148.2 |  |  | 324.1 |  |  | 697.2 |  |  | 682.3 |  |  | 791.0 |
Other immunology | 0.8 |  |  | 20.0 |  |  | 15.3 |  |  | 114.4 |  |  | 12.1 |  |  | 17.6 |
Total immunology | 2,057.9 |  |  | 1,892.8 |  |  | 1,881.8 |  |  | 1,739.6 |  |  | 1,451.8 |  |  | 1,479.0 |
Neuroscience: |  |  |  |  |  |  |  |  |  |  |
Zyprexa(5) | 79.4 |  |  | 30.4 |  |  | 39.6 |  |  | 1,615.4 |  |  | 306.5 |  |  | 390.7 |
Emgality® | 482.2 |  |  | 462.8 |  |  | 434.5 |  |  | 196.0 |  |  | 188.1 |  |  | 142.7 |
Other neuroscience | 134.4 |  |  | 119.2 |  |  | 140.7 |  |  | 371.1 |  |  | 439.2 |  |  | 750.3 |
Total neuroscience | 696.0 |  |  | 612.4 |  |  | 614.8 |  |  | 2,182.5 |  |  | 933.8 |  |  | 1,283.7 |
Other: |  |  |  |  |  |  |  |  |  |  |
Forteo® | 335.5 |  |  | 367.3 |  |  | 441.6 |  |  | 197.7 |  |  | 245.8 |  |  | 360.3 |
Cialis® | 26.1 |  |  | 35.2 |  |  | 10.6 |  |  | 355.3 |  |  | 552.1 |  |  | 707.9 |
COVID-19 antibodies(6) | — |  |  | 2,008.9 |  |  | 1,978.0 |  |  | — |  |  | 14.7 |  |  | 261.4 |
Other | 97.7 |  |  | 144.2 |  |  | 136.1 |  |  | 109.9 |  |  | 151.3 |  |  | 233.9 |
Total other | 459.3 |  |  | 2,555.7 |  |  | 2,566.4 |  |  | 662.9 |  |  | 964.0 |  |  | 1,563.5 |
Revenue | $ | 21,791.0 |  |  | $ | 18,190.0 |  |  | $ | 16,811.0 |  |  | $ | 12,333.1 |  |  | $ | 10,351.3 |  |  | $ | 11,507.4 |
Numbers may not add due to rounding. (1) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR. (2) Humalog revenue includes insulin lispro. (3) Basaglar revenue includes Rezvoglar®. (4) Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations. (5) Zyprexa revenue includes sale of the rights for the olanzapine portfolio. (6) COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations. The following table summarizes revenue by geographical area:
|  |  |  | 2023 |  | 2022 |  | 2021
Revenue(1): |  |  |  |  |  |
U.S. |  | $ | 21,791.0 |  |  | $ | 18,190.0 |  |  | $ | 16,811.0 |
Europe |  | 6,174.7 |  |  | 4,299.2 |  |  | 4,776.8 |
Japan |  | 1,672.6 |  |  | 1,747.3 |  |  | 2,367.0 |
China |  | 1,539.7 |  |  | 1,452.8 |  |  | 1,661.4 |
Other foreign countries |  | 2,946.2 |  |  | 2,852.0 |  |  | 2,702.2 |
Revenue |  | $ | 34,124.1 |  |  | $ | 28,541.4 |  |  | $ | 28,318.4 |
Numbers may not add due to rounding. (1) Revenue is attributed to the countries based on the location of the customer or other party
Schedule of Amounts Recorded for Contract Liabilities | The following table summarizes contract liability balances:
| 2023 |  | 2022
Contract liabilities | $ | 193.6 |  |  | $ | 219.2 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration